Texas is currently home to 4879 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Recruiting
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of sacituzumab tirumotecan with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: University of Texas MD Anderson Cancer Center ( Site 6920), Houston, Texas
Conditions: Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
SpaceIT Hydrogel System for Perirectal Spacing
Recruiting
To evaluate the safety and effectiveness of the SpaceIT™ Hydrogel System in patients undergoing External Beam Radiotherapy (EBRT) for the treatment of prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Midtown Urology Associates, Austin, Texas
Conditions: Prostate Cancer
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
Recruiting
The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to that of healthy matched control participants and to evaluate the safety and tolerability of nemtabrutinib.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/12/2025
Locations: Texas Liver Institute ( Site 0002), San Antonio, Texas
Conditions: Hepatic Impairment (HI)
A Study of RSLV-132 in Females With Sjögren's Syndrome
Recruiting
The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are: * Does RSLV-132 improve the cardinal symptoms of Sjogren's including fatigue, dryness and pain? * Does RSLV-132 improve the tiredness/fatigue caused by Sjogren's? * What are the blood levels of RSLV-132 over time? * What is the immune (antibody) response in the body to RSLV-132? * What is the safety profile of R... Read More
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
06/12/2025
Locations: Resolve Clinical Site, Katy, Texas
Conditions: Primary Sjögren Syndrome
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Recruiting
The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
06/12/2025
Locations: Children's Health, Dallas, Texas
Conditions: Glioma
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Recruiting
RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/12/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Generalized Myasthenia Gravis (gMG)
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
Recruiting
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/12/2025
Locations: Cedar Health Research, LLC, Dallas, Texas
Conditions: Migraine
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.
Recruiting
This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Thyroid Eye Disease
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery
Recruiting
This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
QTX3034 in Patients With KRAS G12D Mutation
Recruiting
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: MD Anderson, Houston, Texas
Conditions: Solid Tumors
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
Recruiting
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually endstage liver disease. Fazirsiran is a medicine that reduces the creation of... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/12/2025
Locations: Texas Liver Institute American Research Corporation, San Antonio, Texas
Conditions: Alpha1-Antitrypsin Deficiency
Polypill for Prevention of Cardiomyopathy
Recruiting
This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 25, 50 or 100 mg, and finerenone 10 mg daily. The study duration is 6 months, and participants will be randomized to either polypill therapy or simultaneous prescription of the individual drugs. The primary outcome is change in peak VO2 and adhe... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/12/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Type 2 Diabetes, High Blood Pressure